Towards the creation of HCV-resistant liver cells for transplantation

Information

  • Research Project
  • 8012481
  • ApplicationId
    8012481
  • Core Project Number
    R43DK083104
  • Full Project Number
    3R43DK083104-01S1
  • Serial Number
    83104
  • FOA Number
    PA-06-397
  • Sub Project Id
  • Project Start Date
    3/1/2010 - 14 years ago
  • Project End Date
    1/31/2012 - 12 years ago
  • Program Officer Name
    DENSMORE, CHRISTINE L
  • Budget Start Date
    3/1/2010 - 14 years ago
  • Budget End Date
    1/31/2012 - 12 years ago
  • Fiscal Year
    2010
  • Support Year
    1
  • Suffix
    S1
  • Award Notice Date
    2/24/2010 - 14 years ago
Organizations

Towards the creation of HCV-resistant liver cells for transplantation

DESCRIPTION (provided by applicant): We propose to carry out foundational studies to characterize the Hepatitis C infectivity of candidate human liver cell transplant products. In order to achieve these studies, we propose to a) assess the HCV infectivity of different fetal and adult liver cell populations, and 2) determine whether shRNA directed against HCV infectivity determinants, such as CD81, can be expressed stably in liver cell populations. PUBLIC HEALTH RELEVANCE: Liver disease is a leading source of mortality in the US. Although liver transplantation is an option for some of patients suffering from liver disease, the scarceness of donor livers makes it difficult for patients to undergo the transplant, and many die waiting for a suitable organ. The transplantation of hepatocytes, rather than whole livers may circumvent many of the limitations of the orthotopic liver transplants. Additionally, almost all of the patients receiving a liver transplant for HCV-associated end-stage liver disease (ESLD) experience re-infection of their graft. Unfortunately, effective anti-HCV therapy for many patients remains elusive. A cell therapy may provide a safe alternative that could be available to more patients. The production of HCV-resistant liver cells will ensure that, upon transplantation, these cells provide the patient not only with the basic liver functions, but also provide an HCV-free liver cell reservoir. In the best case scenario, the liver cells that will be isolated from the healthy organ will be expandable, and HCV-resistant. As the first step in creating these biologically active and transplantable cells, StemCells, Inc. has isolated a population of cells, the human liver engraftable cells (hLECs), that have progenitor/stem cell properties. We propose to use these cells as the starting material, and, in conjunction with shRNA silencing technology, accomplish proof-of-principle studies that will lead to the creation of a transplantable, biologically active, HCV-resistant liver cell product.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    98685
  • Sub Project Total Cost
  • ARRA Funded
    True
  • CFDA Code
    701
  • Ed Inst. Type
  • Funding ICs
    NIDDK:98685\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    STEMCELLS, INC.
  • Organization Department
  • Organization DUNS
    605291285
  • Organization City
    PALO ALTO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    943041213
  • Organization District
    UNITED STATES